Alamar Biosciences, Inc. (NASDAQ:ALMR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Alamar Biosciences, Inc. (NASDAQ:ALMR) has received a consensus recommendation of “Moderate Buy” from the five research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $30.00.

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. started coverage on shares of Alamar Biosciences in a research report on Tuesday. They set an “overweight” rating and a $30.00 price objective on the stock. Bank of America started coverage on shares of Alamar Biosciences in a research note on Tuesday. They set a “neutral” rating and a $27.00 price target for the company. Leerink Partners assumed coverage on shares of Alamar Biosciences in a research report on Tuesday. They issued an “outperform” rating and a $35.00 price objective on the stock. Wall Street Zen raised shares of Alamar Biosciences to a “hold” rating in a research note on Saturday, April 25th. Finally, Stifel Nicolaus began coverage on Alamar Biosciences in a research report on Tuesday. They set a “buy” rating and a $28.00 target price for the company.

Alamar Biosciences Trading Up 3.3%

Shares of Alamar Biosciences stock traded up $0.78 on Tuesday, reaching $24.66. The company had a trading volume of 14,548 shares, compared to its average volume of 327,310. Alamar Biosciences has a 1 year low of $21.50 and a 1 year high of $27.20.

Alamar Biosciences (NASDAQ:ALMR) last released its quarterly earnings results on Friday, May 8th. The company reported ($1.74) earnings per share for the quarter. The company had revenue of $26.04 million during the quarter.

Insider Buying and Selling at Alamar Biosciences

In other Alamar Biosciences news, major shareholder Innovation Fund Gp Illumina II bought 235,294 shares of the firm’s stock in a transaction dated Monday, April 20th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $3,999,998.00. Following the completion of the transaction, the insider owned 507,076 shares in the company, valued at $8,620,292. This trade represents a 86.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nicholas Naclerio bought 235,294 shares of the stock in a transaction dated Monday, April 20th. The shares were bought at an average cost of $17.00 per share, with a total value of $3,999,998.00. Following the completion of the purchase, the director directly owned 507,076 shares of the company’s stock, valued at approximately $8,620,292. This trade represents a 86.57% increase in their position. The SEC filing for this purchase provides additional information.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.